Medical NewsCancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009
More Medical News
Non-Small Cell Lung Cancer (NSCLC)
Please note- The EPG Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre is for Doctors and other Healthcare Professionals.
The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]).
At the start of the millennium, it was estimated that there were 10 million new cancer cases worldwide per annum
The causes of lung cancer are thought to be almost exclusively environmental, although susceptibility is modulated by protective elements such as genetic factors and diet.1
The staging of lung cancer is based on the size and invasiveness of the primary tumour (T), absence, presence and degree of regional lymph node (N) involvement, and the metastatic spread to distant organs and lymph nodes (M), or TNM system.
In around 5% of cases, usually of early-stage disease, initial presentation is a chance finding during routine examination for other conditions and no symptoms are evident.
Following presentation and diagnosis of NSCLC, thorough examination allows determination of the disease stage to provide a prognosis at the individual patient level.
The treatment strategies for NSCLC are principally dictated by clinical stage with modulation according to patient preferences and characteristics such as age and PS
The four primary treatment modalities used in the management of patients with NSCLC are:2
- Surgery
- Radiation therapy
- Combination chemotherapy
- Targeted therapy
Enter the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre
What’s in the Non-Small Cell Lung Cancer (NSCLC) Knowledge Centre?
- Home
- Non-small Cell Lung Cancer
- Causes
- Risk Factors
- Histology/Pathology
- Disease Staging/Prognosis
- TNM Systems
- Factors that affect prognosis
- Signs and Symptoms
- Diagnosis
- Early Stage disease (stage I, II, IIIA)
- Treatment Strategies
- Advanced disease (stage IV)
- Quality of Life in advanced NSCLC
- Future Strategies
- Treatment Therapies
- Chemotherapy
- First-line Therapy
- Second-line Therapy
- Unmet clinical need in advanced NSCLC
- Targeted therapies - Overview of cytotoxic drugs
- Recent developments in Cancer Cell Biology
- Current therapy - Erlotinib
- Resources
- Downloads - Physicians Materials
- Patient
- Downloads - Patient support
References:
1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S–49S.
2. Putnam JB, Fossella FV, Komaki R, eds. Implementation of multidisciplinary care in the treatment of patients with lung cancer. In: Fossella FV, Komaki R, Putnam JB, eds. Lung Cancer. New York, NY: Springer-Verlag; 2003:1-24
-
Alimta 100mg/500mg powder for concentrate - 61.55%
... malignant pleural mesothelioma. Non-small cell lung cancer: ALIMTA in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ALIMTA is indicated as monotherapy ... -
Gemcitabine 200mg Powder for Solution for Infusion - 61.12%
... contraindicated. Non-Small Cell Lung Cancer : Locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. Palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer . Pancreatic Cancer: Locally advanced ... -
TARCEVA Film-Coated Tablets - 60.64%
Non-small cell lung cancer (NSCLC) : Tarceva is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of at least one prior chemotherapy regimen. When prescribing Tarceva, factors associated with prolonged survival should be taken into ... -
AVASTIN Solution for Infusion - 59.92%
... of patients with metastatic breast cancer. Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Avastin in combination ... -
Gemzar 200mg powder for solution for infusion - 59.72%
... cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin, is indicated as first-line treatment of patients with locally advanced or metastatic non-small cell ... -
PHOTOFRIN - 59.65%
Photodynamic therapy (PDT) with Photofrin is indicated for: palliative treatment of obstructing endobronchial non-small cell lung cancer; and palliative treatment of obstructing oesophageal cancer ...